Collaboration leverages AbbVie's expertise in oncology and immunology drug development and Neomorph's leading molecular glue discovery platform Neomorph to receive an upfront payment and is eligible ...

Please provide your email address to receive an email when new articles are posted on . Biogen Inc. and Neomorph Inc. have announced a partnership geared toward research and development of molecular ...

The collaboration aims to discover and develop molecular glue degrader clinical candidates for priority targets to Biogen. Collaboration leverages Neomorph's leading molecular glue discovery platform ...

AbbVie and Neomorph are forming a partnership and option-to-license agreement to develop molecular glue degraders, aiming to introduce a new class of treatments across oncology and immunology.

Biogen (NASDAQ:BIIB) has agreed to pay Neomorph up to $1.45B plus royalties on any future products as part of a new collaboration deal for the discovery and development of molecular glue degraders for ...

SAN DIEGO--(BUSINESS WIRE)--Neomorph, Inc., a venture backed biotechnology company solving critical problems in human health through the discovery and development of innovative new medicines against ...

Novo Nordisk is spending $1.46 billion to discover, develop and commercialize molecular glue degraders from San Diego-based biotech Neomorph. As part of the collaboration and licensing agreement, ...

As a science fiction fan, I've always shuddered at the thought of an alien bursting out of my chest. But I've never thought about what it might be like to be the one doing the chest-bursting. That is, ...